



Pelagia Research Library

Der Pharmacia Sinica, 2011, 2 (1): 182-193



Der Pharmacia Sinica

ISSN: 0976-8688
CODEN (USA): PSHIBD

Formulation and characterization of medicated chewing gum delivery of Diphenhydramine Hydrochloride

Farhad Mehta*, C. Kartikayen, Piyush Trivedi

Department of Pharmaceutics, School of Pharmaceutical Sciences, Rajiv Gandhi Prodhogiki
Vishwavidyalaya, Bhopal (M.P.), India

ABSTRACT

The release of a drug from chewing gum is dependent upon its water solubility. Water soluble substances are released rapidly and completely from chewing gum and methods are available which retard their release from chewing gum to provide an extended release profile. Slightly water-soluble drugs are released slowly and incompletely from chewing gum and require special formulation techniques to produce a satisfactory release profile. Studies evaluating the potential application of medicated and non-medicated chewing gum in the treatment of local diseases in the oral cavity are described. Specific examples of the use of chewing gum as a delivery system for dental health, smoking cessation and antifungal therapy are cited. Few drugs are suitable candidates for incorporation into chewing gum formulations for the intention of their systemic delivery. Know-how derived from the development and manufacture of already existing medicated and non-medicated chewing gum, supplemented with today's knowledge of the principles of pharmaceutical formulation, constitute the basis for the development of the medicinal chewing gum of tomorrow.

Key words: Buccal delivery; Increased release; Sustained release; Bioavailability; Therapeutic effect; Dental health; Oral candidiasis; Smoking cessation.

INTRODUCTION

Medicated chewing gum is solid, single-dose preparations that have to be chewed & not swallowed; chewing gums contain one or more active ingredient that is released by chewing. A medicated chewing gum is intended to be chewed for a certain period of time, required to deliver the dose, after which the remaining mass is discarded. During the chewing process the drug

contained in the gum product is released from the mass into saliva & could be absorbed through the oral mucosa or swallowed reaching stomach for gastro-intestinal absorption.

Empiric findings had shown that people chewing gum was better at keeping awake and alert, and that gum chewing eased tension. The acceptance of this somewhat anecdotally understood effect achieved a better scientific basis in the summer 2002 when L Wilkinson and co-workers [1] published a study of 75 healthy volunteers who were led through a number of cognitive, recognition, and memory tests. The results provided the first evidence that the chewing of gum can improve episodic memory and working memory.

The anecdotal effect of chewing gum on weight loss has also been studied recently. In December 1999, The New England Journal of Medicine [2] revealed that while chewing gum, energy expenditure increases from 58 kcal per hour to 70 kcal per hour – an increase of 19%. The conclusion was that if a person chewed gum during walking hours, this alone would mean a yearly weight loss of more than 5 kg. Though there are many other interesting anecdotal effects that result from gum chewing, such as the easing of blocked ears.

The advantages of utilizing a chewing gum drug delivery system are highlighted by T Imfeld³ in his 1999 review of gum chewing and oral health.

There are two absorption pathways which are possible to introduce the active ingredient into the systemic circulation giving rise to a systemic effect. Drug absorbed directly via the buccal membrane avoids metabolism in the G.I tract & the first-pass effect of the liver; it might therefore be to administer a reduce dose in chewing gum compared to other oral delivery system.

Local effect

To obtain the optimal local effect to treat a health condition requires that the relevant active substance be available at a therapeutic level near or within the tissue being treated, regardless of the delivery system. For the treatment of oral cavity conditions, it is beneficial to achieve a therapeutic level of active substance in the saliva, and different formulations (e.g. oral gel, mouth rinse) have been created to meet this goal. Chewing gum is an ideal drug delivery system for this treatment area; the active substances are released as the gum is chewed, thus providing the potential for a high level of active substance to obtain local effect in the oral cavity. It is possible to design a chewing gum that releases active substances over a prolonged period. The “Oral health and caries prevention” and “Oral fungal infection” provide a more comprehensive review of the advantages of chewing gum drug delivery systems for the local treatment of oral health conditions.

Systemic effect

Systemic effects of active substances released from chewing gum can be achieved in two ways [3] in the “traditional” way, by swallowing the active substance, or buccally via absorption through the oral mucosa. The latter is of special interest. As buccal absorption avoids first-pass hepatic metabolism of the active substance, it could provide better bioavailability. Buccal absorption may also lead to fast onset of the active substance as the vascular supply of the buccal mucosa is rich and lead directly into the systemic circulation. Chewing gum promotes buccal

absorption by releasing active substances at carefully controlled rates, thus allowing for extended exposure in the oral cavity. [4]

The objective of the present work is to develop and characterize medicated chewing gum delivery of diphenhydramine hydrochloride for motion sickness, it is also planned to identify the important formulation parameters affecting the behaviour of medicated chewing gum. The drug which is used in this work is an antihistamine H₁ receptor antagonist. [5]

Antihistamines are suitable candidate for motion sickness; their antiemetic effect appears to be based on anticholinergic, antihistaminic & sedative properties. Chemoreceptor trigger zone (CTZ) located in area postrema & the nucleus tractus solitarius (NTS) has variety of receptor H₁, D₂ serotonin 5-HT₃, cholinergic M & Opioid μ through which emetic signal are relayed which are possible target for antiemetic drug. Antiemetic drug metoclopramide, domperidone, cisapride (prokinetic drug), neuroleptic drug, chlorpromazine, prochlorperazine, haloperidol, 5-HT₃ antagonists ondansetron are less suitable for treatment of motion sickness, they are more suitable for emesis induced by cytotoxic drug or emesis caused due to post operative vomiting.

Diphenhydramine Hydrochloride based on its higher salivary solubility & fewer side effects (no extra pyramidal effect) is the suitable candidate for formulation of MCG for prevention of motion sickness.

MATERIALS AND METHODS

Diphenhydramine Hydrochloride was purchased from Indoco remedies Ltd, Mumbai. Gum base purchased from SGI Pvt Ltd, Bangalore. Disodium hydrogen phosphate, Potassium dihydrogen phosphate, Sodium chloride, Phosphoric acid, Polyvinyl acetate, Ether, Acetone, Ethanol, Sodium hydroxide, Sodium carbonate, Dichloromethane, Calcium carbonate, Polyisobutylene, Glycerol, Paraffin wax, Sorbitol and Glycerin purchased from Central drug house Ltd, Delhi. Analytical grade methanol was purchased from Loba chem. Pvt Ltd, Mumbai. n-Octanol was purchased from S.D. Fine chem. Ltd, Mumbai.

Preparation of medicated chewing gum:

Each ingredient was weighed accurately. Synthetic gum base and wax was melted, to this molten mass, previously weighed quantity of plasticizer was added and then mixed thoroughly, the melting was carried out in porcelain dish at about 35^oC to 45^oC on water bath. The mixture was allowed to cool at temperature of 15 to 20^oC, then the physical homogenous mixture of Diphenhydramine Hydrochloride, talc and sucrose was added with continuous stirring, so that to ensure even distribution of drug. [7] Then flavor and color was added at the end of mixing. After 30 minutes of stirring, this mass was allowed to cool and poured in a round mould having diameter 10mm & depth 0.7mm. (fig1)

Characterization of medicated chewing gum:

1. Physical evaluation of Medicated Chewing Gum: All Medicated Chewing Gum formulations were visually inspected; various physical properties of gum base were studied on

basis of their solubility studies, relative humidity, color and moisture absorption.[6] Following parameters were studied:

- a) Weight variation: Weight variation of all formulation was done by method described in experimental work.
- b) Physical evaluation of MCG: All formulation prepared by above procedure were physically evaluated for following parameters, Appearance, Color, Stickness, Hardness, Weight variation and Plasticity.
- c) Hardness/Plasticity: Due to absence of any reported method, it was decided to use the Monsanto type hardness tester for determination of hardness of all MCG formulations.
- d) Weight variation: Weight of ten chewing gum was taken in one batch, then average weight is calculated, from that standard deviation is calculated.
- e) Stickiness: MCG placed on plane surface, 250gm cylindrical hammer collide on to it for period of ten minutes. The frequency of hammering was about 30 per minute. After 10 minutes, sticking of mass to hammered surface was observed and reported.

2. Chew out study: Chew out study protocol was formulated based on input from Fertin Pharma pvt ltd. Denmark, one of the world largest manufactures of medicated chewing gum. Following scoring pattern was developed from specific input from Fertin Pharma Pvt. Ltd. Denmark. Initial phase of chew out study included various parameters like texture, elasticity, smoothness, crankiness, softness, cheesiness, sweetness, cooling effect, hardness, juiciness & lubricating feel.[5]

3. *In vitro* drug release based on:

- i) Change in twisting angle of upper mastication jaw from ($5^{\circ} - 30^{\circ}$).
- ii) Change in distance b/w upper & lower masticating Jaw from (1-2mm).
- iii) Change in chewing frequency of lower masticating Jaw from (20 strokes / minute to 120 strokes / minute).
- iv) Change in temperature from ($30^{\circ}\text{C} - 40^{\circ}\text{C}$).

The chewing gum was inserted between the pistons on to the lower chewing surface. The chewing procedure consisted of up and down stroke of lower masticating surface combined with twisting movement of upper masticating surface, thereby masticating the chewing gum and consequently agitating the test medium. The optimized chewing frequency employed in the study was 60 ± 2 strokes per minute. At predominant time interval aliquot of the artificial saliva, were removed and assayed for drug content by UV spectrophotometric analysis. The release medium was replaced with fresh artificial saliva after each sample was taken.[8-10]

4. Stability study of synthetic gum base: 10 gm of synthetic gum base was stored in bottle at $30^{\circ}\text{C} \pm 2^{\circ}\text{C}/65\% \text{RH} \pm 5\% \text{RH}$ (According to WHO guidelines for stability) for a period of six months. After six months the gum was examined for signs of ageing and physical deformalities.[11]

RESULTS AND DISCUSSION

Melting Point: The Melting point of the Diphenhydramine hydrochloride was found to be in the range of 168°C to 172°C. Melting point was found to be 170°C. It means that the drug used is in pure form.

Identification Test: The λ max for Diphenhydramine hydrochloride was found to be 258nm in phosphate buffer having pH 6.8.

Infrared Spectroscopy: The IR values of Diphenhydramine hydrochloride shows the peak at following value which shows characteristic of drug.

IR spectra of Diphenhydramine hydrochloride indicated characteristic peaks belonging to major functional groups which are similar to standard peaks, such as aromatic CH stretch (3035.41 cm^{-1}), -N(CH₃)₂ HCl ($2400\text{--}2700\text{ cm}^{-1}$), aromatic rings skeletal vibrations ($1592.91, 1407\text{ cm}^{-1}$), CH₂ bending (1461.78 cm^{-1}), CH₃ bending (1342.21 cm^{-1}), C-O-C stretching (1106.94 cm^{-1}) and C-H out of plane deformation of mono-substituted phenyl ($717, 760\text{ cm}^{-1}$).

Physiochemical properties of synthetic gum: Softening range of synthetic gum base is suitable for formulation of medicated chewing gum.

Moisture absorption study of synthetic gum: Synthetic gum base absorb very less percentage of moisture means gum base is stable during shelf life.

***In vitro* drug release: *In vitro* drug release based on:**

- i) Change in twisting angle of upper mastication jaw from ($5^0 - 30^0$).
- ii) Change in distance b/w upper & lower masticating Jaw from (1-2mm).
- iii) Change in chewing frequency of lower masticating Jaw from (20 strokes / minute to 120 strokes / minute).
- iv) Change in temperature from ($30^0\text{C} - 40^0\text{C}$).

The chewing gum was inserted between the pistons on to the lower chewing surface. The chewing procedure consisted of up and down stroke of lower masticating surface combined with twisting movement of upper masticating surface, thereby masticating the chewing gum and consequently agitating the test medium. The optimized chewing frequency employed in the study was 60 ± 2 strokes per minute. At predominant time interval aliquot of the artificial saliva, were removed and assayed for drug content by UV spectrophotometric analysis. The release medium was replaced with fresh artificial saliva after each sample was taken.

On setting 20^0 (which is optimized setting for twisting angle) as twisting angle movement for upper masticating Jaw after, 45 min. 99% drug release was noted, which emphasize that increasing twisting angle increase rate of release of drug significantly. It was noted that for optimized formulation that as we decrease the distance between the upper & lower masticating surface from 2 mm to 1mm, this lead to increase in rate of release since the force acting on the gum is larger with 1mm setting. When distance between Jaws increase from 1mm to 2mm for

MCG % drug release decrease and time interval needed for drug release increases. Chewing frequency of lower masticating Jaw is important factor in the mastication process. As we increase the frequency of chewing or movement of lower masticating Jaw the drug release profile shows significant increase.

As we increase the number of frequency of the lower masticating jaw the release profile of drug show increase in lower time interval. High kneading speeds between the Jaws of the chewing apparatus led to increase in release rate of drug and decrease in the time interval for release is obtained.

Table.1 *In vitro* drug release with setting of Chewing Frequency 60 Strokes/min

S. No.	Chewing Frequency (Strokes/min)	Time Interval (min.)	Cumulative % Drug Release (Formulation Code)			
			MCG 1	MCG 6	MCG 7	MCG 8
1.	60	0	0	0	0	0
2.	60	5	24	20	19	25
3.	60	10	35	31	29	35
4.	60	15	45	42	41	46
5.	60	20	56	53	51	57
6.	60	25	68	64	62	70
7.	60	30	77	74	72	77
8.	60	35	88	81	80	87
9.	60	40	94	89	87	93
10.	60	45	99	95	94	99
11.	60	50	-	-	-	-

Fig 1: Percentage drug release with chewing frequency 60 Strokes/min




Fig 2: Percentage drug release with chewing frequency 120 Strokes/min





Table .2 : *In vitro* drug release with setting of Chewing Frequency 120 Strokes/min

S. No.	Chewing Frequency (Strokes/min)	Time Interval (min.)	Cumulative % Drug Release (Formulation Code)			
			MCG 1	MCG 6	MCG 7	MCG 8
1.	120	0	0	0	0	0
2.	120	5	59	56	53	60
3.	120	10	67	64	62	70
4.	120	15	78	74	72	80
5.	120	20	89	85	82	90
6.	120	25	98	94	91	98
7.	120	30	-	-	-	-
8.	120	35	-	-	-	-
9.	120	40	-	-	-	-
10.	120	45	-	-	-	-
11.	120	50	-	-	-	-

Table .3: *In vitro* drug release with setting of distance between the Jaws 1.5mm

S. No.	Distance between Jaws (mm)	Time Interval (min.)	Cumulative % Drug Release (Formulation Code)			
			MCG 1	MCG 6	MCG 7	MCG 8
1.	1.5	0	0	0	0	0
2.	1.5	5	24	20	19	25
3.	1.5	10	35	31	29	35
4.	1.5	15	45	42	41	46
5.	1.5	20	56	53	51	57
6.	1.5	25	68	64	62	70
7.	1.5	30	77	74	72	77
8.	1.5	35	88	81	80	87
9.	1.5	40	94	89	87	93
10.	1.5	45	99	95	94	99
11.	1.5	50	-	-	-	-

Fig .3: Percentage drug release with distance between the Jaws 1.5mm

Table 4: *In vitro* drug release with setting of twisting angle at 5°

S. No.	Twisting Angle (degrees)	Time Interval (min.)	Cumulative % Drug Release (Formulation Code)			
			MCG 1	MCG 6	MCG 7	MCG 8
1.	5	0	0	0	0	0
2.	5	5	10	8	9	11
3.	5	10	18	15	16	15
4.	5	15	29	26	23	25
5.	5	20	40	37	33	38
6.	5	25	52	48	40	49
7.	5	30	60	54	45	57
8.	5	35	70	60	51	65
9.	5	40	74	69	60	69
10.	5	45	84	77	71	79
11.	5	50	93	86	84	89

As the temp increase from 30°C-40°C there was no significant effect on drug release profile for optimized batch of MCG.

MCG-1 formulation was found to be best optimized formulation. Gum base consist of polyisobutylene (10%) as elastomer having high molecular weight which assist in gum forming elastic property of MCG. Glycerol (30%) was used as plasticizer in formation of gum base. Elastomer & plasticizer are responsible for cohesiveness of the gum base. Paraffin wax (15%) used as texture enabling agent for the gum base. Soya oil (7%) was used as lipid enabling agent for gum base. Wax and soya oil are responsible for cooling effect and lubricating feel of the MCG. Lecithin (3%) was used as an emulsifier which was responsible for juicy feel of the gum. Peppermint (3%) was used as a flavouring agent which provided sufficient taste masking and flavour for the medicated chewing gum.

It was noted that for optimized formulation, decreasing the distance b/w the upper & lower masticating surface from 2 mm to 1mm lead to increase in the rate of release since the force acting on the gum is larger with 1mm setting. When distance between Jaws increase from 1mm to 2 mm for MCG, % drug release decrease while time interval needed for drug release increases.

Fig .4: Percentage drug release with twisting angle 5°





Fig 5: MCG poured in mould

Table.5 Different formulation and ratio of ingredient %w/w

S.NO	Ingredient	MCG 1	MCG 6	MCG 7	MCG 8
1	Diphenhydramine Hydrochloride	10	10	10	10
2	Gum base	29	29	29	29
3	Powdered sorbitol	43	33	43	53
4	Sorbitol solution 70%	21	21	11	11
5	Glycerine	5	15	15	5
6	Peppermint crystal	1	1	1	1
7	Lecithin with 50% oil	0.50	0.50	0.50	0.50
8	Aspartame	0.33	0.33	0.33	0.33

Table 6.; Physiochemical properties of synthetic gum base after stability studies

S. NO (For MCG 1,MCG 6,MCG 7 and MCG 8 formulations)	Properties	Observations
1.	Color(before ageing)	White to off white
2.	Color(after ageing)	White to off white
3.	Softening range(before ageing)	75 to 85 ⁰ C
4.	Softening range(after ageing)	75 to 85 ⁰ C
5.	Texture(before ageing)	Gummy
6.	Texture(after ageing)	Gummy

CONCLUSION

Medicated chewing gum (MCG) are solid, single dose preparations with a base consisting mainly of gums that are intended to be chewed but not swallowed. Medicated chewing gum (MCG) is a novel drug delivery system containing masticatory gum base with pharmacologically active ingredient and intended to use for local treatment of mouth diseases or systemic absorption through oral mucosa. MCG is considered as vehicle or a drug delivery system to administer active principles that can improve health and nutrition.

Though chewing gum as a drug delivery system has gained wide acceptance only within smoking cessation and oral health care, clinical trials have proven that there are therapeutic advantages to be gained by using chewing gum as a drug delivery system through exploiting the effects achieved by chewing gum per se, the convenience of the delivery system, and the possibilities of having buccal absorption or local effect of an active substance. Furthermore, one of the trials has indicated that chewing gum as drug delivery systems are possibly safer for active substances that are susceptible to abuse. Chewing gum formulations may also be less prone to accidental overdose.

The development costs of new active pharmaceutical ingredients have increased dramatically and thus the pharmaceutical companies are now more and more focusing on new initiatives to achieve maximum commercial advantage from their current products and brands.

A Medicated Chewing gum formulation is easy to take as no water or swallowing is required. This makes it especially beneficial for patients with nausea or persons who experience swallowing problems. Additionally, chewing gum enhances motility of the GI-tract which could

be helpful in overcoming nausea. Compared to injections and suppositories, medicated chewing gum are highly preferred by the patients. Furthermore, as chewing is required to have the active substance released, the risk of overdose will be diminished.

Fast onset of action is one of the most desirable effects to be obtained from the treatment when suffering from nausea. A Medicated Chewing gum formulation can facilitate fast onset of action. If the active substance is absorbed buccally, onset of action will occur fast – without being delayed by passing through the gastrointestinal tract and liver. Fast onset of action can also be expected if the active substance is not absorbed buccally, as the active substance will be dissolved before reaching the gastrointestinal tract and, therefore, be readily absorbed. Furthermore, in case of buccal absorption, it is likely that the dose could be decreased due to the avoidance of first pass metabolism, and thus, fewer side effects will be seen. As the fear of side effects is predominant among patients, a Medicated Chewing gum formulation with lesser amount of active ingredient is likely to be favored by the patients.

Children do not like to take tablets or suppositories nor do they like to have injections. Any improvement in the formulation which could diminish the discomfort and battle in connection with taking the medication would be appreciated by children and their parents and thereby leading to increased acceptance and compliance.

Antihistamines are suitable candidate for motion sickness; their antiemetic effect appears to be based on anticholinergic, antihistaminic & sedative properties. Chemoreceptor trigger zone (CTZ) located in area postrema & the nucleus tractus solitarius (NTS) has variety of receptor H_1 , D_2 serotonin $5-HT_3$, cholinergic M & Opioid μ through which emetic signal are relayed which are possible target for antiemetic drug.

Antiemetic drug metoclopramide, domperidone, cisapride (prokinetic drug), neuroleptic drug, chlorpromazine, prochlorperazine, haloperidol, $5-HT_3$ antagonists ondansetron are less suitable for treatment of motion sickness, they are more suitable for emesis induced by cytotoxic drug or emesis caused due to post operative vomiting. Diphenhydramine Hydrochloride based on its higher salivary solubility and fewer side effects (no extra pyramidal effect) is the suitable candidate for formulation of MCG for prevention of motion sickness.

Chewing gum is no longer seen simply as confectionary. Wrigley have recently created a healthcare division to use chewing gum as a delivery system for active ingredients that provide health benefits dental health chewing gum is here to stay, as is medicated gum for smoking cessation A bright future for a preparation with a long history.

Nausea can occur acutely or with a very short warning. Thus, the patient requires not only fast onset of action, but also a product that can be taken anywhere without too much difficulty. A medicated chewing gum formulation addresses these concerns perfectly.

Patients value benefits that are easily understood. Patients will favor products that are convenient and will help them carry on with their daily lives without betraying outward signs of illness or disease. Consequently, a medicated chewing gum formulation is ideal.

REFERENCES

- [1] Rathbone. M.J; Hadgraft.J; Roberts.M.S.J, Modified-release drug delivert technology, Marcel Dekker, **2002**, pp(1-8).
- [2] http://www.fertin.com/fileadmin/pdf/Doc_on_MCWG_booklet.pdf.
- [3] Rassing M. R; Jacobsen.J, Nielsen.H.M., Chewing gum as a drug delivery system. 2nd edd, Ellermann Carecom International, Copenhagen, Denmark, **2003**.
- [4] ReamRonald.L; Corriveau.ChristineL; Wokas.William.J; Tounge.Jr; ThomasM; Greenberg. Micheal.J., Pharmaceutical chewing gum formulation, US 7078052,(**2006**).
- [5] Mochizuki K; Yokomichi, F. Process for preparation of chewing gum, U.S 4,000,321,(**1976**).
- [6] Vries.M.E; Bodde.H.E; Verhoef.J.C; Junginger.H.E., *Crit Rev Ther Drug Carr Sys*, **1991**, 8, 271-303.
- [7] Cherukuri G; Subraman R; Bikkina, Kirshnayya, Tabletted chewing gum composition and method of preparation, US 4753805,(**1988**).
- [8] Subraman.R; John.M; Jack.E, Aradhana.Edward J; Carlos D; Gitchell Joe, Medicated chewing gum delivery system for nicotine, US 6344222.,(**2002**).
- [9] Manmode A.S; Mahajan N.M, Sanghai D.B; Tekede B.W., *IJPRD*,(**2005**),22,346.
- [10] Amir.H; Shojaei; Bret.Berner; Xiaoling.Li. *Pharma Res*,(**1998**),15(8),1182-1188.
- [11] Hughes, Lyn, Buccal, Dissolution of active substances, US 20030087457,(**2003**)